What next for newly diagnosed glioblastoma?

被引：25

作者：

Domingo-Musibay, Evidio ^{[1
]}

Galanis, Evanthia ^{[1
]}

机构：

[1] Mayo Clin, Div Med Oncol, Rochester, MN 55905 USA

来源：

FUTURE ONCOLOGY | 2015年 / 11卷 / 24期

关键词：

bevacizumab; glioblastoma; newly diagnosed; novo-TTF; radiation therapy; temozolomide; INTEGRATED GENOMIC ANALYSIS; CARMUSTINE BCNU WAFERS; RANDOMIZED PHASE-III; GENE-THERAPY; OPEN-LABEL; ADJUVANT TEMOZOLOMIDE; LOCAL CHEMOTHERAPY; STANDARD TREATMENT; RADIATION-THERAPY; GLIADEL WAFERS;

D O I：

10.2217/fon.15.258

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Glioblastoma is the most common primary brain tumor in adults. Despite current multimodality treatment including surgical resection and temozolomide-based chemoradiotherapy, median survival is only 14-16 months. Characterization of molecular alterations in glioblastoma has identified prognostic subgroups and therapeutic opportunities for clinical trials across glioblastoma subsets. Following a number of negative Phase III trials testing temozolomide dose intensification and angiogenesis inhibition, recent interim analysis data indicate survival prolongation with use of a device (Optune (TM)) delivering alternating electrical field therapy in newly diagnosed glioblastoma patients. In this review, we present an overview of the data supporting the current standard of care and discuss novel experimental therapies in early and late phase clinical testing including devices, small molecule drugs, angiogenesis inhibitors, oncolytic virotherapy and immunotherapy.

引用

页码：3273 / 3283

页数：11

共 53 条

[1] Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients [J].

Adair, Jennifer E. ;

Johnston, Sandra K. ;

Mrugala, Maciej M. ;

Beard, Brian C. ;

Guyman, Laura A. ;

Baldock, Anne L. ;

Bridge, Carly A. ;

Hawkins-Daarud, Andrea ;

Gori, Jennifer L. ;

Born, Donald E. ;

Gonzalez-Cuyar, Luis F. ;

Silbergeld, Daniel L. ;

Rockne, Russell C. ;

Storer, Barry E. ;

Rockhill, Jason K. ;

Swanson, Kristin R. ;

Kiem, Hans-Peter .

JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (09) :4082-4092

[2]

Afra D, 2002, LANCET, V359, P1011

[3] Newly diagnosed glioblastoma patients treated with an autologous heat shock protein peptide vaccine: PD-L1 expression and response to therapy [J].

Bloch, Orin ;

Raizer, Jeffrey J. ;

Lim, Michael ;

Sughrue, Michael ;

Komotar, Ricardo ;

Abrahams, Jonathan ;

O'Rourke, Donald ;

D'Ambrosio, Anthony ;

Bruce, Jeffrey N. ;

Parsa, Andrew .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

[4] The Somatic Genomic Landscape of Glioblastoma [J].

Brennan, Cameron W. ;

Verhaak, Roel G. W. ;

McKenna, Aaron ;

Campos, Benito ;

Noushmehr, Houtan ;

Salama, Sofie R. ;

Zheng, Siyuan ;

Chakravarty, Debyani ;

Sanborn, J. Zachary ;

Berman, Samuel H. ;

Beroukhim, Rameen ;

Bernard, Brady ;

Wu, Chang-Jiun ;

Genovese, Giannicola ;

Shmulevich, Ilya ;

Barnholtz-Sloan, Jill ;

Zou, Lihua ;

Vegesna, Rahulsimham ;

Shukla, Sachet A. ;

Ciriello, Giovanni ;

Yung, W. K. ;

Zhang, Wei ;

Sougnez, Carrie ;

Mikkelsen, Tom ;

Aldape, Kenneth ;

Bigner, Darell D. ;

Van Meir, Erwin G. ;

Prados, Michael ;

Sloan, Andrew ;

Black, Keith L. ;

Eschbacher, Jennifer ;

Finocchiaro, Gaetano ;

Friedman, William ;

Andrews, David W. ;

Guha, Abhijit ;

Iacocca, Mary ;

O'Neill, Brian P. ;

Foltz, Greg ;

Myers, Jerome ;

Weisenberger, Daniel J. ;

Penny, Robert ;

Kucherlapati, Raju ;

Perou, Charles M. ;

Hayes, D. Neil ;

Gibbs, Richard ;

Marra, Marco ;

Mills, Gordon B. ;

Lander, Eric ;

Spellman, Paul ;

Wilson, Richard .

CELL, 2013, 155 (02) :462-477

[5] Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma [J].

Brown, Christine E. ;

Badie, Behnam ;

Barish, Michael E. ;

Weng, Lihong ;

Ostberg, Julie R. ;

Chang, Wen-Chung ;

Naranjo, Araceli ;

Starr, Renate ;

Wagner, Jamie ;

Wright, Christine ;

Zhai, Yubo ;

Bading, James R. ;

Ressler, Julie A. ;

Portnow, Jana ;

D'Apuzzo, Massimo ;

Forman, Stephen J. ;

Jensen, Michael C. .

CLINICAL CANCER RESEARCH, 2015, 21 (18) :4062-4072

[6] Comprehensive genomic characterization defines human glioblastoma genes and core pathways [J].

Chin, L. ;

Meyerson, M. ;

Aldape, K. ;

Bigner, D. ;

Mikkelsen, T. ;

VandenBerg, S. ;

Kahn, A. ;

Penny, R. ;

Ferguson, M. L. ;

Gerhard, D. S. ;

Getz, G. ;

Brennan, C. ;

Taylor, B. S. ;

Winckler, W. ;

Park, P. ;

Ladanyi, M. ;

Hoadley, K. A. ;

Verhaak, R. G. W. ;

Hayes, D. N. ;

Spellman, Paul T. ;

Absher, D. ;

Weir, B. A. ;

Ding, L. ;

Wheeler, D. ;

Lawrence, M. S. ;

Cibulskis, K. ;

Mardis, E. ;

Zhang, Jinghui ;

Wilson, R. K. ;

Donehower, L. ;

Wheeler, D. A. ;

Purdom, E. ;

Wallis, J. ;

Laird, P. W. ;

Herman, J. G. ;

Schuebel, K. E. ;

Weisenberger, D. J. ;

Baylin, S. B. ;

Schultz, N. ;

Yao, Jun ;

Wiedemeyer, R. ;

Weinstein, J. ;

Sander, C. ;

Gibbs, R. A. ;

Gray, J. ;

Kucherlapati, R. ;

Lander, E. S. ;

Myers, R. M. ;

Perou, C. M. ;

McLendon, Roger .

NATURE, 2008, 455 (7216) :1061-1068

[7]

Chinot OL, 2014, NEW ENGL J MED, V370, P709, DOI 10.1056/NEJMoa1308345

[8] Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines [J].

Clarke, Michelle J. ;

Mulligan, Evan A. ;

Grogan, Patrick T. ;

Mladek, Ann C. ;

Carlson, Brett L. ;

Schroeder, Mark A. ;

Curtin, Nicola J. ;

Lou, Zhenkun ;

Decker, Paul A. ;

Wu, Wenting ;

Plummer, E. Ruth ;

Sarkaria, Jann N. .

MOLECULAR CANCER THERAPEUTICS, 2009, 8 (02) :407-414

[9] Involvement of the mismatch repair system in temozolomide-induced apoptosis [J].

D'Atri, S ;

Tentori, L ;

Lacal, PM ;

Graziani, G ;

Pagani, E ;

Benincasa, E ;

Zambruno, G ;

Bonmassar, E ;

Jiricny, J .

MOLECULAR PHARMACOLOGY, 1998, 54 (02) :334-341

[10] Tumor treating fields: a new frontier in cancer therapy [J].

Davies, Angela M. ;

Weinberg, Uri ;

Palti, Yoram .

PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: PRIX GALIEN USA 2012, 2013, 1291 :86-95

← 1 2 3 4 5 6 →